Shruti Shah, MD
Interventional Pain Medicine · Holmdel, NJNPI 1114158755
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,238 of the $4,773 with a category attached, or 88.8%. It is spread thinly across 31 manufacturers, the largest accounting for just 20.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $1,389 and has fallen 56.3% since, to $607 in 2025.
Across 141 payments — averaging $33.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SPR Therapeutics, Inc$972
- Si-bone, Inc.$726
- Curonix LLC$706
- Medtronic$419
- Boston Scientific$361
- Scilex Pharmaceuticals Inc.$257
- plus $1K from 25 others
What the payments were for
- Travel & lodging$51611%
- Food & beverage$4,23889%
- Education$180%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SPR Therapeutics, Inc | 8 | $972 |
| Si-bone, Inc. | 12 | $726 |
| Curonix LLC | 11 | $706 |
| Medtronic(2 entities) | 10 | $419 |
| Boston Scientific | 15 | $361 |
| Scilex Pharmaceuticals Inc. | 18 | $257 |
| Kowa Pharmaceuticals America, Inc. | 18 | $199 |
| Biotronik NRO, Inc. | 5 | $191 |
| Nevro Corp. | 3 | $147 |
| Averitas Pharma Inc. | 5 | $108 |
| Globus Medical(2 entities) | 3 | $94 |
| Vertos Medical, Inc. | 1 | $69 |
| Bioventus LLC | 3 | $65 |
| Nalu Medical, Inc. | 3 | $52 |
| Johnson & Johnson | 3 | $49 |
| Abbott | 3 | $48 |
| Novo Nordisk | 3 | $41 |
| Azurity Pharmaceuticals, Inc. | 2 | $31 |
| Merck | 2 | $27 |
| Fidia Pharma USA Inc. | 1 | $27 |
| Almatica Pharma LLC | 2 | $27 |
| Phadia US Inc. | 1 | $20 |
| Saluda Medical Americas, Inc. | 1 | $18 |
| Tonix Medicines, Inc. | 1 | $17 |
| Lucid Diagnostics Inc. | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Astellas Pharma US Inc | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| AstraZeneca | 1 | $15 |
| Amgen | 1 | $15 |
| IBSA Pharma Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,773 in reported general payments places this provider in the 60th percentile of 82 interventional pain medicine providers in New Jersey.
See all interventional pain medicine providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nucynta ErTapentadol Hcl | 12 | $12,834 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 468 | $6,835 |
| Gabapentin | 594 | $4,435 |
| ZtlidoLidocaine | 13 | $4,402 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 135 | $1,881 |
| Tramadol Hcl ErTramadol Hcl | 25 | $1,825 |
| Acetaminophen-CodeineAcetaminophen With Codeine | 104 | $1,629 |
| Lidocaine | 24 | $1,458 |
| Morphine Sulfate ErMorphine Sulfate | 59 | $1,194 |
| Cyclobenzaprine Hcl | 206 | $933 |
| Diclofenac Sodium | 32 | $877 |
| Tramadol Hcl | 170 | $753 |
| Duloxetine Hcl | 51 | $616 |
| Tizanidine Hcl | 77 | $531 |
| Pregabalin | 26 | $403 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Scilex Pharmaceuticals Inc.Ztlido | $257 | $4,40213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 82 interventional pain medicine providers in New Jersey.
Other interventional pain medicine in Holmdel
- Ali ValimahomedHolmdel$415K
- Ajay VarmaHolmdel$9K
- Youssef JosephsonWest Deptford$496K
- Saurabh DangEdgewater$157K
- Gabriele JasperBrick$114K
- Matthew LippChatham$67K
- Didier DemesminSomerset$33K
- Steve AydinFranklin Lakes$22K
- Kieran SlevinHainesport$21K
- John CoccaroToms River$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.